The company behind the most popular weight loss drugs this year has been catapulted to the most valuable company in Europe, toppling luxury brand parent company LVMH.
Novo's stock continued to climb after the holiday weekend, reaching a new market cap of $429 billion Tuesday, as LVMH's stock declined. The company's rise also makes Novo more valuable than the GDP of its home country, Denmark .
The injectables are part of a growing market for GLP-1s, drugs that mimic a hormone in the body to slow digestion, which have been around for some time. But stronger weight loss results compared to previous drugs in the category catapulted Ozempic and Wegovy into the mainstream.of some doses — a problem that Novo Nordisk is actively trying to solve with its contract manufacturers. But even so, the drugmaker has said it is unlikely to meet the skyrocketing demand in the near future.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Wegovy supply from Novo Nordisk has arrived in UK, Simple Online Pharmacy saysLONDON (Reuters) - UK-based Simple Online Pharmacy has received stock of Novo Nordisk's weight-loss drug Wegovy, a company spokesperson said on ...
Lire la suite »
Wegovy supply from Novo Nordisk has arrived in UK, Simple Online Pharmacy saysLONDON (Reuters) - UK-based Simple Online Pharmacy has received stock of Novo Nordisk's weight-loss drug Wegovy, a company spokesperson said on ...
Lire la suite »
Pent-up private Wegovy demand prompts UK availability concernsBy Maggie Fick LONDON (Reuters) - People in Britain who can afford to pay out of their own pocket may get easier access to Novo Nordisk's weight-loss ...
Lire la suite »
Pent-up private Wegovy demand prompts UK availability concernsBy Maggie Fick LONDON (Reuters) - People in Britain who can afford to pay out of their own pocket may get easier access to Novo Nordisk's weight-loss ...
Lire la suite »
Business is booming for the maker of weight-loss drugs Wegovy and Ozempic — so much so that it is threatening luxury giant LVMH's crown as Europe's most valuable firmNovo Nordisk's at-home injections are in high demand, but some insurers say they won't cover the high prices.
Lire la suite »
Marketmind: Shedding pounds, buying dollarsDanish drugmaker Novo Nordisk's red-hot weight-loss injection hits British stores this week and investors just can't get enough of the shares of what has become Europe's most valuable listed firm. Investors are also focusing on English football club Manchester United, whose shares fell 18% on Tuesday in their steepest one-day decline. Part two of the dollar rally came from higher yields as top-rated companies including Unilever Capital Corp, Philip Morris International and Volkswagen tapped U.S. debt markets in the traditional post-Labor Day rush for financing.
Lire la suite »